Clik here to view.
Celltrion Healthcare showcases positive 1-year results for novel subcutaneous...
VIENNA Celltrion Healthcare today announced new 1-year data from a randomised controlled trial to evaluate the pharmacokinetics (PK), efficacy and safety of CT-P13 subcutaneous (SC) formulation...
View ArticleClik here to view.
Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to...
MILAN & MORRISTOWN, N.J. Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of...
View ArticleClik here to view.
Clik here to view.
Octapharma Group 2019年销售收入与营业收入均实现强劲增长
瑞士拉亨 (美国商业资讯)–Octapharma首席执行官兼董事长Wolfgang Marguerre在评论集团业绩时表示：“Octapharma在2019年取得特别强劲的业绩。我们在所有三个治疗领域均实现良好增长。我们继续大笔投资研发，用于发现和开发改变生活的全新疗法，以及提高我们的血浆收集能力，从而确保未来为患者提供挽救生命的产品。我们的全新皮下免疫球蛋白(SCIG)...
View ArticleClik here to view.
Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver...
View ArticleClik here to view.
CANbridge Pharmaceuticals Completes US$98 Million Series D Financing
BEIJING CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced the completion...
View ArticleAVITA Medical Half-Year Financial Report for Fiscal 2020
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical Limited (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis...
View ArticleClik here to view.
拓臻生物公布其非酒精性脂肪性肝炎（NASH）候选药物-具有肝脏选择性的法尼醇X受体（FXR）激动剂TERN-101-临床Ⅰ期试验安全性和药效学研究结果
美国加州福斯特城与中国上海 (美国商业资讯)–Terns Pharmaceuticals 拓臻生物—一家专注非酒精性脂肪性肝炎（NASH）和癌症创新疗法研发的全球生物制药公司，今天宣布已完成其NASH候选药物FXR激动剂TERN-101的Ⅰ期临床研究，研究数据表明在所有用药剂量TERN-101均显示出良好的耐受性，以及达到可能与有效治疗相关的生物靶向作用。...
View ArticleClik here to view.
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation...
BOTHELL, Wash. & TOKYO Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug...
View ArticleClik here to view.
RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007...
TOKYO RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced...
View ArticleClik here to view.
Vifor Pharma and Fresenius Kabi create joint venture in China for i.v. iron...
ST GALLEN, Switzerland Vifor Pharma today announced a strategic partnership with Fresenius Kabi to create a new joint company based in the People’s Republic of China expanding its access to the...
View ArticleClik here to view.
Efficient Assistance, YITU AI Aids Epidemic Prevention and Control of...
BEIJING Since the outbreak of COVID-19, Yitu Healthcare responded quickly and launched an operation of multiple departments. The main R & D team sacrificed their vacations, worked around the...
View ArticleClik here to view.
Vantage 2019 Review: Standout Year for Pharma, Anchored by Strong Fourth...
LONDON & BOSTON & TOKYO Stock market gains and dealmaking activity in Q4 clinched the biopharma sector’s strong performance in 2019 – a stark reversal of the declines seen in the final...
View ArticleClik here to view.
Efficient Assistance, YITU AI Aids Epidemic Prevention and Control of...
BEIJING On February 4th, Shanghai Public Health Clinical Center, one of the authoritative institutions in the field of infectious diseases in China and the core unit for the treatment of COVID-19 in...
View ArticleClik here to view.
Terns Pharmaceuticals、NASH治療薬として開発中の肝臓選択的...
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleClik here to view.
Adisseo and Calysta Establish a Joint-Venture to Commercialize FeedKind®, an...
MENLO PARK, Calif. Bluestar Adisseo Company (Adisseo), a world leader in feed additives for animal nutrition, and the world’s leading alternative protein producer, Calysta, today signed an agreement...
View ArticleClik here to view.
Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an...
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SUZHOU, China Harbour BioMed (HBM) today announced completion of a Phase 1 study of HBM9161, a fully human anti-FcRn monoclonal antibody, to...
View ArticleClik here to view.
Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for...
PRINCETON, N.J. Bristol-Myers Squibb Company (NYSE: BMY) today announced Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Opdivo (nivolumab) for the treatment of patients with...
View ArticleClik here to view.
Genetron Health and InnoCare Team Up In Partnership To Accelerate the...
BEIJING Genetron Holding Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, has announced a strategic partnership with Beijing InnoCare Pharma...
View Article